4DMedical receives TGA approval for CTVQ in Australia
Filed with ASX · · 4 pages · English
Summary by 6ix AI
4DMedical Ltd. has received approval from the Therapeutic Goods Administration for its CT:VQ™ imaging solution in Australia, allowing for commercial deployment across the country. This approval marks a significant milestone as CT:VQ™ is now cleared for use in multiple international markets, enhancing its potential as a standard for functional lung assessment. The company plans to pursue Medicare reimbursement for CT:VQ™, leveraging its regulatory achievements and clinical evidence to support this initiative.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Story so far
Earlier from 4DMedical
- 4DMedical targets US$2.5B PE market entry for CTVQ
- 4DMedical creates EU platform via contextflow acquisition
- CTVQ enters US Outpatient Market via SimonMed 170 sites
- Major publication validates CTVQ for lung surgery
- GSK contract, UK clearance for CTVQ, and ASX 200 inclusion
Later from 4DMedical
- 4DMedical Receives TGA Approval for CT: VQ™, Bringing Non-Contrast Ventilation-Perfusion Imaging to Australia
- Pause in trade
- US Bill directs VA to adopt 4D lung imaging
- Quarterly Activity Report and Appendix 4C
- Update - Proposed issue of securities - 4DX
Follow 4DMedical into a list and get an email when it puts out news.
Follow 4DMedical